693774-26-4

Basic information

• Product Name: 3-BROMOPHENYL CYCLOPROPYL KETONE
• Synonyms: 3-BROMOPHENYL CYCLOPROPYL KETONE
• CAS NO: 693774-26-4
• Molecular Formula: C₁₀H₉BrO
• Molecular Weight: 225.08
• Mol File: 693774-26-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 303.1°C at 760 mmHg
• Flash Point: 97.2°C
• Appearance: /
• Density: 1.537g/cm³
• Vapor Pressure: 0.000952mmHg at 25°C
• Refractive Index: 1.615
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-BROMOPHENYL CYCLOPROPYL KETONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMOPHENYL CYCLOPROPYL KETONE(693774-26-4)
• EPA Substance Registry System: 3-BROMOPHENYL CYCLOPROPYL KETONE(693774-26-4)

Safety Data

• Hazardous Substances Data: 693774-26-4(Hazardous Substances Data)

Usage

Description

3-Bromophenyl cyclopropyl ketone, with the molecular formula C10H9BrO, is a yellow to brown liquid chemical compound characterized by a distinctive odor. It is a versatile building block in organic synthesis, known for its ability to participate in various chemical reactions, and is primarily utilized in the synthesis of pharmaceuticals and organic compounds.

Uses

Used in Pharmaceutical Synthesis:
3-Bromophenyl cyclopropyl ketone is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to undergo multiple chemical reactions, contributing to the development of new and improved medications.
Used in Organic Compound Synthesis:
In the field of organic chemistry, 3-Bromophenyl cyclopropyl ketone serves as a valuable building block for creating more complex molecules, facilitating the advancement of research and innovation in organic compound development.
Safety Precautions:
It is crucial to handle 3-Bromophenyl cyclopropyl ketone with care, as it is classified as a hazardous chemical. Exposure may result in skin, eye, and respiratory system irritation, necessitating proper safety measures during its use and storage.

InChI:InChI=1/C10H9BrO/c11-9-3-1-2-8(6-9)10(12)7-4-5-7/h1-3,6-7H,4-5H2

Upstream product

• 925430-09-7 tricyclopropylbismuthane 
• 591-18-4 1-Bromo-3-iodobenzene 
• 201230-82-2 carbon monoxide 
• 79134-92-2 (3-bromophenyl)(cyclopropyl)methanol 
• 3132-99-8 m-bromobenzoic aldehyde 
• 108-36-1 1,3-dibromobenzene 
• 147356-78-3 cyclopropanecarboxylic acid N-methoxy-N-methylamide 
• 1711-09-7 3-bromobenzoyl chloride 

Downstream Products

• 1372806-11-5 5-(3-bromophenyl)-5-cyclopropyl-3-methylimidazolidine-2,4-dione 
• 1372806-26-2 5-(3-bromophenyl)-5-cyclopropyl-3-methyl-2-thioxoimidazolidin-4-one 
• 1049686-36-3 5-(3-bromophenyl)-5-cyclopropyl-2-imino-3-methylimidazolidin-4-one 
• 1049669-09-1 C₁₁H₁₂BrNO₂ 
• 1370656-89-5 C₁₂H₁₄BrNO₂ 
• 1370656-90-8 C₁₃H₁₃BrN₂OS 
• 1049639-30-6 C₁₃H₁₄BrN₃O 
• 887911-70-8 C₁₉H₁₈ClN₃O 
• 887911-83-3 C₁₉H₁₇Cl₂N₃O 
• 887911-67-3 5-cyclopropyl-2-imino-5-(3-(3-methoxyphenyl)phenyl)-3-methylimidazolidin-4-one 
• 887911-65-1 C₂₀H₁₈N₄O 
• 887911-56-0 C₁₈H₁₈N₄O 
• 887913-84-0 C₁₉H₂₀N₄O₂ 
• 887910-96-5 C₁₉H₁₇N₅O 

Relevant articles and documents

SMALL MOLECULE MODULATORS OF IL-17

The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositions comprising said

Silylium-Ion-Promoted (5+1) Cycloaddition of Aryl-Substituted Vinylcyclopropanes and Hydrosilanes Involving Aryl Migration

A transition-metal-free (5+1) cycloaddition of aryl-substituted vinylcyclopropanes (VCPs) and hydrosilanes to afford silacyclohexanes is reported. Catalytic amounts of the trityl cation initiate the reaction by hydride abstraction from the hydrosilane, and further progress of the reaction is maintained by self-regeneration of the silylium ions. The new reaction involves a [1,2] migration of an aryl group, eventually furnishing 4- rather than 3-aryl-substituted silacyclohexane derivatives as major products. Various control experiments and quantum-chemical calculations support a mechanistic picture where a silylium ion intramolecularly stabilized by a cyclopropane ring can either undergo a kinetically favored concerted [1,2] aryl migration/ring expansion or engage in a cyclopropane-to-cyclopropane rearrangement.

Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor

From an initial lead 1, a structure-based design approach led to identification of a novel, high-affinity iminohydantoin BACE1 inhibitor that lowers CNS-derived Aβ following oral administration to rats. Herein we report SAR development in the S3 and F′ subsites of BACE1 for this series, the synthetic approaches employed in this effort, and in vivo data for the optimized compound.